- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02557529
Progressive Resistance Training in Head and Neck Cancer Patients During Concomitant Chemoradiotherapy
Progressive Resistance Training in Head and Neck Cancer Patients During Concomitant Chemoradiotherapy - The DAHANCA 31 Study
72 patients with head and neck cancer, undergoing primary treatment with radiation therapy and concomitant weekly cisplatin, will be recruited to this multicentre trial.
Randomized 1:1 to either 12-week progressive resistance training (PRT) program or control arm, starting together with concomitant chemoradiotherapy (CCRT) Stratified by centre, gender, p16-status and body mass index (BMI) below or above 30.
Primary endpoint is difference in change in lean body mass (LBM) between the groups and the endpoint is reduction of LBM loss in intervention arm by 25% compared to control.
Secondary endpoints include side-effects to treatment, change in body composition, physical function and strength, and compliance to PRT. Questionnaires on QoL, diet, voluntary exercise and work affiliation will also be registered.
Blood samples for explorative analyses will be drawn and optional muscle biopsies drawn for proteomics analyses and histological analyses.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The PRT program will start about the onset of radiotherapy. The program consists of 7 exercises in training machines and involves the major muscle groups of the body.
The program has previously been found to successfully restore the loss of lean body mass (LBM) in head and neck cancer patients post-treatment. A group based approach will be used to facilitate a social and motivating training environment for the patients. A pilot study (NCT02068950) showed feasibility of PRT during CCRT.
In addition to baseline data (height, tumor stage, performance status, etc), the following parameters will be registered: Weight, patient reported side effects, as well as a questionnaire on amount of physical activity and food intake.
Physical function and strength will be tested at baseline, after the course of chemoradiotherapy and at the end of the 12-week PRT programme, and at 6 and 12 months follow-up. DXA scans for body composition will be performed using a Lunar iDXA (GE Healthcare).
Blood samples will be drawn at regular intervals during the 12 weeks and at follow-up.
Patient reported quality of life (EORTC Quality of Life Questionnaire (QLQ)-C30 and QLQ-H&N35) will also be registered.
Muscle biopsies will be taken three times: at baseline, after treatment and after 12-weeks PRT.
Study duration is expected to be 18 months and an additional 12 months for follow-up.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Herlev, Denmark, 2730
- Department of Oncology, Copenhagen University Hospital, Herlev
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with biopsy verified head and neck squamous cell carcinoma referred for primary curatively intended treatment.
Candidates for concomitant chemoradiotherapy (2Gyx33-34; 6F/W; weekly cisplatin 40mg/m2, max. 70 mg/weekly) according to Danish Head and Neck Cancer Group (DAHANCA) guidelines (T1-4, N1-3, M0)
- Performance status 0-1
- At least 18 years of age.
Exclusion Criteria:
- BMI below 20.5
- diabetes
- corticosteroid treatment for other diseases
- Tonsillectomy within the last week before inclusion.
- hemoglobin below 6 mmol/l
- leucocytes below 2.5 x 10^9 /l
- thrombocytes below 50 x 10^9 /l
- comorbidities, social, familial or geographical conditions, that could compromise attendance or results
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Progressive Resistance Training
12 weeks progressive resistance training (PRT) during and after concomitant chemoradiotherapy.
Also optional/voluntary physical activity performed on their own is registered, as well as diet diary.
|
12 weeks supervised resistance training program.
Details of the program: 12 weeks, 3 sessions per week, 7 exercises in training machines (leg press, leg curl, hamstring curl, chest press, lateral pull down, sit-ups and back extensions).
In general 2-3 sets of 8-15 repetitions will be performed following a progression plan starting with more repetitions at lower intensity progressing to fewer repetitions at higher intensity during the 12-week period (American College of Sports Medicine Position Stand)
Weekly diary of performed physical activity using the Physical Activity Score (PAS) during the 12-weeks intervention
Other Names:
Weekly diet diary during the 12-weeks intervention
|
Active Comparator: Control
Control arm.
Optional/voluntary physical activity performed on their own is registered, as well as diet diary.
|
Weekly diary of performed physical activity using the Physical Activity Score (PAS) during the 12-weeks intervention
Other Names:
Weekly diet diary during the 12-weeks intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in LBM (lean body mass)
Time Frame: at 12-weeks post PRT
|
change in kilograms
|
at 12-weeks post PRT
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in LBM (lean body mass)
Time Frame: at 6 weeks, and 6 and 12 months post RT
|
change in kilograms
|
at 6 weeks, and 6 and 12 months post RT
|
Fat mass
Time Frame: at 6 and 12 weeks, and 6 and 12 months post RT
|
change in kilograms
|
at 6 and 12 weeks, and 6 and 12 months post RT
|
Weight loss
Time Frame: at 6 and 12 weeks, and 6 and 12 months post RT
|
in kilograms
|
at 6 and 12 weeks, and 6 and 12 months post RT
|
Patient reported pain
Time Frame: at 6 and 12 weeks, and 6 and 12 months post RT
|
Measured by NRS-scale
|
at 6 and 12 weeks, and 6 and 12 months post RT
|
Patient reported Quality of Life
Time Frame: at 6 and 12 weeks, and 6 and 12 months post RT
|
QLQ-C30 questionnaire
|
at 6 and 12 weeks, and 6 and 12 months post RT
|
Muscle strength
Time Frame: at 6 and 12 weeks, and 6 and 12 months post RT
|
measured using chest press and leg press
|
at 6 and 12 weeks, and 6 and 12 months post RT
|
Chair rise
Time Frame: at 6 and 12 weeks, and 6 and 12 months post RT
|
measured using 30 s. chair rise
|
at 6 and 12 weeks, and 6 and 12 months post RT
|
arm curls
Time Frame: at 6 and 12 weeks, and 6 and 12 months post RT
|
measured using 30 s. arm curls
|
at 6 and 12 weeks, and 6 and 12 months post RT
|
Stair climb
Time Frame: at 6 and 12 weeks, 6 and 12 months
|
steps/sec
|
at 6 and 12 weeks, 6 and 12 months
|
Compliance to PRT program
Time Frame: at 12 weeks post PRT
|
No. of attended sessions out of total
|
at 12 weeks post PRT
|
Physical activity
Time Frame: at 6 and 12 weeks, and 6 and 12 months post RT
|
measured by PAS (physical activity scale)
|
at 6 and 12 weeks, and 6 and 12 months post RT
|
Percent of patients with feeding tubes
Time Frame: at 6 and 12 weeks, and 6 and 12 months post RT
|
at 6 and 12 weeks, and 6 and 12 months post RT
|
|
Resumption of work
Time Frame: At 12 months follow-up
|
No. of days from end of radiotherapy until back at work at full time (or the hours of work per week as before therapy)
|
At 12 months follow-up
|
Percent relapses
Time Frame: at 12 months follow-up
|
Percent of patients having relapse within 12 months after radiotherapy
|
at 12 months follow-up
|
Cytokines
Time Frame: at 3, 6, 8, 10, and 12 weeks
|
Measurement of different cytokines, changes over time and after bout of PRT.
Will be measured regularly during the 12 weeks of PRT.
|
at 3, 6, 8, 10, and 12 weeks
|
Muscle biopsies
Time Frame: at 6 and 12 weeks, and at 12 months follow-up
|
protein will be measured using the proteomic approach.
Muscle fiber type and size will be evaluated.
|
at 6 and 12 weeks, and at 12 months follow-up
|
Patient satisfaction
Time Frame: at 12 weeks
|
Study specific questionnaire regarding pros and cons of attending the study
|
at 12 weeks
|
NK-cells
Time Frame: at 3 and 12 weeks
|
Measuring NK-cells.
NK-cells may increase after exercise and show tumor inhibiting effect.
|
at 3 and 12 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Julie Gehl, Herlev Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DAHANCA 31
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Neoplasms
-
Robert FerrisAmgenCompletedHead and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neoplasms, Head and Neck | Cancer of the Head and Neck | Cancer of Neck | Upper Aerodigestive Tract Neoplasms | Neck Neoplasms | Cancer of the Head | Cancer of the Neck | UADT Neoplasms | Cancer of Head | Head Neoplasms | Head, Neck Neoplasms | Neoplasms, Head and other conditionsUnited States
-
Assiut UniversityRecruitingHead and Neck Cancer | Head and Neck Neoplasms | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and NeckEgypt
-
IRCCS Policlinico S. MatteoNestlé Health Science Spain; Akern SrlCompletedHead-neck CancerItaly
-
University of California, San FranciscoCompleted
-
Thomas Jefferson UniversityCompletedHead and Neck CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedHead And Neck CancerUnited States
-
AZ Sint-Jan AVRecruiting
-
IntraGel TherapeuticsNot yet recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHead and Neck CarcinomaUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisActive, not recruiting
Clinical Trials on Progressive Resistance Training
-
Pamukkale UniversityCompletedTotal Knee ArthroplastyTurkey
-
Bangor UniversityBetsi Cadwaladr University Health BoardCompletedChronic Kidney DiseaseUnited Kingdom
-
Stian EllefsenSykehuset Innlandet HFRecruiting
-
University of Illinois at ChicagoNational Heart, Lung, and Blood Institute (NHLBI)Active, not recruitingHypertension | Sarcopenia | High Blood PressureUnited States
-
Glasgow Caledonian UniversityTerminatedParalysis | Trauma, Nervous System | Spinal Cord Diseases | Spinal Cord Injuries | QuadriplegiaUnited Kingdom
-
University of SydneyUnknown
-
National Geriatric HospitalNot yet recruitingDiabetes | SarcopeniaVietnam
-
Beth Israel Deaconess Medical CenterCompleted
-
Herlev HospitalCompletedHead and Neck CancerDenmark